|
|
|
Bioabsorbable
|
The primary goal of bioabsorbable stents is to aid in the prevention of acute vessel reclosure, the stents then slowly dissolve or disappear within days or weeks after the clinical procedure is finished. For more information on bioabsorbable stents, please view our articles below. |
|
The Year in Review and ?Where to Next?? Interventional Cardiology 2007
2006 has been an exceptional year for advances in interventional cardiology. These developments have demonstrated both the positive and negative aspects of important clinical advances. New devices and studies have focused our attention on unexpected events related to drug-eluting stents (DES), the approaching deployment of catheter-based percutaneous valvular implantation and repair, new devices for chronic total occlusions and forthcoming bioabsorbable stents.
|
Selected News from the American College of Cardiology Annual Scientific Sessions: March 24-27, 2007, New Orleans, Louisiana
The American College of Cardiology (www.acc.org) represents the majority of board-certified cardiovascular physicians in the United States. Its mission is to advocate for quality cardiovascular care through education, research, promotion, development and application of standards and guidelines, and to influence health care policy.
|
News from the Transcatheter Cardiovascular Therapeutics Meeting (TCT)
Held in Washington, D.C., October 22?27, 2006
|
News from the Transcatheter Cardiovascular Therapeutics meeting (TCT)
In last year? Dr. Ellis went on to say the results ? However, cardiologists advised that the MACE rates can?
|
May 2004 (Part I)
Enrollment Underway in First Drug-eluting Coronary Stent Registry Assessing Impact of Stent-Deployment Technique on Patient Outcomes eCYPHERSM S.T.L.L.R. Registry to Include 1,500 patients at 50 U.S. Treatment Centers Patient enrollment is underway in the eCYPHERSM S.T.L.L.R.* Registry, the first study specifically designed to evaluate the impact of stent-deployment technique on patient outcomes achieved with the Cypher® Sirolimus-eluting Coronary Stent. Everolimus Eluting Coronary Stent ...
|
The Smaller Contenders for the DES Market
The progress of the major stent manufactures for drug-eluting stent (DES) FDA approval and marketing is well-documented. Boston Scientific Corporation and Cordis Corporation are now battling it out for dominance of this multi-billion dollar industry. Guidant is soon to become a division of Johnson & Johnson or Boston Scientific, and Medtronic is working diligently to receive FDA approval so they can also enter this lucrative market. However, few know that a growing number of smaller companies have also developed DES products.
|
Angiolink's Staple-Mediated VCD Addresses Limitations of Current Technology Part II
Our vascular closure devices today have significant limitations (Table 1). What we really need to do is to develop an ?ideal? vascular closure device (VCD). Thankfully, there are new technologies coming out that hopefully are addressing this issue. Figure 1 is a novel device called the Angiolink EVS? staple device. It is not yet FDA-approved, but Angiolink has just finished doing a pivotal trial and anticipate approval in the fall of 2004. We have worked on this project with Angiolink (Tauton, Massachusetts) for 4 years.
|
CEU Offering: Advanced Stenting Strategies for Complex Coronary Artery Bifurcation Lesions
Percutaneous coronary stenting of bifurcation lesions constitute a challenge for interventional cardiology. It is continuously a main focus of discussion among invasive cardiologists, and has been for over 20 years.
|
The Indiana Heart Hospital
What is the size of your cath lab facility and number of staff members? The Indiana Heart Hospital (TIHH), as part of the Community Health Network, has three cath lab sites with a total of 11 labs. TIHH is the flagship cardiology hospital for a large hospital network. We have four cardiac rooms, two electrophysiology (EP) rooms and one peripheral vascular (PV) room. There are two other hospitals in our network: Community South (CHS), with 2 cath labs, and Community East (CHE), also with 2 cath labs. These two hospitals allow TIHH to float staff between all three hospitals according to shifts in patient volume.
|
The Ten-Minute Interview with? Zokra Musovic, BS, RCIS, FSICP
We are proud to introduce Zorka Musovic, the Treasurer of the Illinois Chapter of the Society of Invasive Cardiovascular Professionals (SICP). Zorka was also recently awarded Fellowship status with the SICP. Fellowship is bestowed upon those individuals who have made significant contributions to the SICP or the field of invasive/diagnostic cardiology. Additional requirement include having sat for and passed the Registered Cardiovascular Invasive Specialist (RCIS) examination, active status with the SICP and CCI (Cardiovascular Credentialing International) and a current staff position at a healthcare facility based in the cardiac cath lab or associated with an invasive cardiovascular technology program. ? SICP Journal Editor for Cath Lab Digest
|
|
|
|
|
|
|
|
On Demand Medical Education
|
|
|
|
|
